News Sentiment

KYNB sentiment intelligence

Kyntra Bio, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 56 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.23 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

75/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.9% over one week, +7.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Kyntra Bio Inc. (KYNB) Sheds 1.5% as Shares Test Key Support Zone - Counter Trend Trade

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 75/100 classification
One-week reaction -4.9% Price reacting lower
Trend fit Trend inactive 7.9% over four weeks
Fair value -54.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 39
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 14
Market source 9
Stock Titan 8
Investing.com 5
dars.gov.et 3
Moomoo 3
GlobeNewswire 3
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 22
Analyst action 5
Balance sheet 2
Guidance 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Stock Titan Direct company coverage

If You Invested $1,000 in KYNTRA BIO INC (KYNB)

This article analyzes the hypothetical returns of investing $1,000 in KYNTRA BIO INC (KYNB). It reveals that an investment made a year ago would currently be worth $788, representing a 21% decrease. The article also provides an overview of Kyntra Bio, Inc.'s business, focusing on

Tone
Negative 39/100
Event
Market update
Published
09 Jul 2026 01:41
Source
Stock Titan
Moomoo Direct company coverage

Oppenheimer Initiates Kyntra Bio(KYNB.US) With Buy Rating, Announces Target Price $35

Oppenheimer has initiated coverage on Kyntra Bio (KYNB.US) with a "Buy" rating. The firm also announced a target price of $35 for the company's shares. This indicates a positive outlook from Oppenheimer on Kyntra Bio's future performance.

Tone
Positive 74/100
Event
Analyst action
Published
08 Jul 2026 05:41
Source
Moomoo
TradingView Direct company coverage

Net margin % of Kyntra Bio, Inc. – DUS:1FG0

This article provides access to the net margin percentage for Kyntra Bio, Inc. (DUS:1FG0) on the TradingView platform. It is a financial data point for the company listed on the Dusseldorf Stock Exchange. The content primarily focuses on the display of this financial metric withi

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 08:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Kyntra Bio, Inc. – DUS:1FG0

This article provides the forward price-to-sales ratio for Kyntra Bio, Inc. (DUS:1FG0) on the Dusseldorf Stock Exchange. It indicates no current trading data and emphasizes that the content focuses on financial metrics for this specific pharmaceutical stock.

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 17:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Kyntra Bio, Inc. – DUS:1FG0

The article presents the enterprise value to revenue forward for Kyntra Bio, Inc. (DUS:1FG0) on the Dusseldorf Stock Exchange. It indicates that the market was closed with no trades recorded for the period. The content is primarily a financial snapshot on TradingView, noting the

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 23:41
Source
TradingView
TradingView Direct company coverage

Price to book forward of Kyntra Bio, Inc. – NASDAQ:KYNB

This article provides access to the "Price to book forward" financial data for Kyntra Bio, Inc. (NASDAQ: KYNB) on the TradingView platform. It highlights that the market is currently closed and no trades have occurred for the stock. The content primarily focuses on navigation and

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 14:11
Source
TradingView
TradingView Direct company coverage

KYNB Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Kyntra Bio, Inc. (KYNB) stock for 2027, based on analyst ratings. It details the company's current stock price, historical performance, volatility, market capitalization, and upcoming earnings report. The piece also includes f

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 12:38
Source
TradingView
TradingView Direct company coverage

Kyntra Bio, Inc. Actuals & Estimates (NASDAQ:KYNB)

Kyntra Bio, Inc. (NASDAQ:KYNB) stock is currently trading at $7.24, showing a 1.73% increase in the past 24 hours. Analysts' future price estimates range from $30.00 to $43.00. The company's last reported earnings were -$3.76 per share, missing the estimate, with revenue at $3.70

Tone
Positive 63/100
Event
Earnings
Published
26 Jun 2026 07:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Kyntra Bio, Inc. – NASDAQ:KYNB

The article focuses on the enterprise value to EBIT forward of Kyntra Bio, Inc. (NASDAQ: KYNB). It provides a snapshot of the company's financial overview within the TradingView platform, detailing market data and analytical tools available for investors. The content appears to b

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Price to book forward of Kyntra Bio, Inc. – TRADEGATE:1FG0

This article provides the "Price to book forward" for Kyntra Bio, Inc. (TRADEGATE:1FG0) and indicates that the market is currently closed with no trades. It is a financial data point presented on the TradingView platform.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 02:10
Source
TradingView
TradingView Direct company coverage

Net debt of Kyntra Bio, Inc. – DUS:1FG0

The article focuses on the net debt of Kyntra Bio, Inc. (DUS:1FG0), traded on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content seems to be a financial data page from TradingView, providing an overview of Kyntra B

Tone
Neutral 50/100
Event
Balance sheet
Published
19 Jun 2026 10:40
Source
TradingView
Stock Titan Direct company coverage

KYNTRA BIO (KYNB) director Ho Maykin awarded 7,000 stock options at $7.13

KYNTRA BIO (KYNB) director Ho Maykin was granted 7,000 stock options, which allows him to purchase common stock at an exercise price of $7.13 per share. These options are part of a compensation award and will vest in four equal quarterly installments from the grant date, expiring

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 03:10
Source
Stock Titan
TradingView Direct company coverage

Price to earnings ratio of Kyntra Bio, Inc. – DUS:1FG0

This article displays the price to earnings ratio for Kyntra Bio, Inc. (DUS:1FG0) on the TradingView platform. The content is primarily a data point regarding the company's financials on the Dusseldorf Stock Exchange, indicating "No trades" at the time of viewing.

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 21:40
Source
TradingView
TradingView Direct company coverage

Kyntra Bio, Inc. Statistics – DUS:1FG0

This page provides detailed financial statistics and ratios for Kyntra Bio, Inc. (DUS:1FG0) listed on the Dusseldorf Stock Exchange. Users can find annual and quarterly data for various metrics, including valuation, profitability, liquidity, solvency ratios, and per-share metrics

Tone
Neutral 50/100
Event
Balance sheet
Published
18 Jun 2026 19:09
Source
TradingView
TradingView Direct company coverage

Basic earnings per share (basic EPS) of Kyntra Bio, Inc. – DUS:1FG0

This article presents the basic earnings per share (basic EPS) for Kyntra Bio, Inc., traded under the symbol DUS:1FG0 on the Dusseldorf Stock Exchange. It includes period values, changes, and change percentages for this financial metric. The data is provided by ICE Data Services

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 18:09
Source
TradingView
Stock Titan Direct company coverage

Kyntra Bio (KYNB) director receives 7,000 options at $7.13 strike

Kyntra Bio director Jeffrey L. Edwards was granted 7,000 stock options with an exercise price of $7.13 per share. These options serve as compensation, vesting in four equal quarterly installments, and expire on June 11, 2036. This grant aligns Edwards' equity incentives with the

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

Kyntra Bio (KYNB) awards 7,000 stock options to director

Kyntra Bio Inc. (KYNB) has awarded its director, James A. Schoeneck, 7,000 stock options with an exercise price of $7.13 per share and an expiration date of June 11, 2036. The options will vest in four equal quarterly installments commencing from the grant date of June 12, 2026.

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

KYNTRA BIO (KYNB) director awarded 7,000 stock options at $7.13 strike

KYNTRA BIO director Michael Kauffman was granted 7,000 stock options with an exercise price of $7.13 per share and an expiration date of June 11, 2036. The options will vest in four equal quarterly installments from the grant date. This transaction, reported via a Form 4 SEC fili

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 23:40
Source
Stock Titan
Investing.com Direct company coverage

Kyntra Bio shareholders elect director and approve executive pay at annual meeting

At its 2026 annual meeting, Kyntra Bio shareholders elected Michael Kauffman, M.D., Ph.D., as a Class III director and approved the compensation for the company's named executive officers on an advisory basis. They also ratified PricewaterhouseCoopers LLP as the independent regis

Tone
Positive 64/100
Event
Market update
Published
17 Jun 2026 09:10
Source
Investing.com
Stock Titan Direct company coverage

Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor

Kyntra Bio (NASDAQ: KYNB) shareholders approved key proposals at their 2026 annual meeting, including the election of Michael Kauffman as a Class III director, advisory approval of executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent regis

Tone
Neutral 50/100
Event
Regulatory and legal
Published
15 Jun 2026 23:09
Source
Stock Titan
GlobeNewswire Direct company coverage

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Kyntra Bio announced new data from its Phase 3 MATTERHORN trial, demonstrating that roxadustat improves transfusion independence in patients with anemia stemming from lower-risk myelodysplastic syndromes (LR-MDS), irrespective of their ring sideroblast status. The findings highli

Tone
Positive 73/100
Event
Market update
Published
12 Jun 2026 06:39
Source
GlobeNewswire
Investing.com South Africa Direct company coverage

Kyntra Bio stock rises on roxadustat MDS trial data By Investing.com

Kyntra Bio shares rose significantly after presenting data from a post hoc analysis of its Phase 3 MATTERHORN trial for roxadustat. The data showed that roxadustat improved transfusion independence in patients with lower-risk myelodysplastic syndromes and high transfusion burden.

Tone
Positive 71/100
Event
Market update
Published
11 Jun 2026 23:54
Source
Investing.com South Africa